在复发时何时应开始治疗 AL 淀粉样变性？早期，以防止器官进展。
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.
机构信息
Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
出版信息
Blood Adv. 2019 Jan 22;3(2):212-215. doi: 10.1182/bloodadvances.2018021253.
Abstract
This article has a companion Counterpoint by Sanchorawala.
摘要
本文有桑乔拉瓦尔的相关反驳文章。
相似文献
1
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.在复发时何时应开始治疗 AL 淀粉样变性？早期，以防止器官进展。
Blood Adv. 2019 Jan 22;3(2):212-215. doi: 10.1182/bloodadvances.2018021253.
2
Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.复发时延迟治疗淀粉样变直至出现症状：细节决定成败。
Blood Adv. 2019 Jan 22;3(2):216-218. doi: 10.1182/bloodadvances.2018021261.
3
Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.AL淀粉样变性中器官反应的深度与生存率提高相关：新提出的器官反应标准。
Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486.
4
Localized Lymph Node Light Chain Amyloidosis.局限性淋巴结轻链淀粉样变。
Intern Med. 2020 Oct 1;59(19):2415-2418. doi: 10.2169/internalmedicine.4651-20. Epub 2020 Jun 30.
5
Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis.浆细胞骨髓瘤合并AL淀粉样变性过程中的腹水
Turk J Haematol. 2018 Mar 1;35(1):71-72. doi: 10.4274/tjh.2016.0262. Epub 2016 Aug 16.
6
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.复发/难治性系统性轻链淀粉样变患者的治疗模式和医疗资源利用情况。
Amyloid. 2018 Mar;25(1):1-7. doi: 10.1080/13506129.2017.1411796. Epub 2018 Jan 5.
7
[Primary amyloidosis].[原发性淀粉样变性]
Med Clin (Barc). 2016 Aug 5;147(3):121-6. doi: 10.1016/j.medcli.2016.02.018. Epub 2016 Apr 13.
8
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.免疫球蛋白轻链淀粉样变性管理中的新挑战：从基础到临床。
Expert Rev Hematol. 2020 Sep;13(9):1003-1015. doi: 10.1080/17474086.2020.1803060. Epub 2020 Aug 11.
9
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.系统性免疫球蛋白轻链淀粉样变性初始治疗后早期治疗失败的预测因素。
Amyloid. 2017 Sep;24(3):183-188. doi: 10.1080/13506129.2017.1351354. Epub 2017 Jul 12.
10
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.尿白蛋白与肌酐比值在肾AL型淀粉样变性诊断及风险分层中的应用
Amyloid. 2017 Mar;24(sup1):68-69. doi: 10.1080/13506129.2017.1293644.
引用本文的文献
1
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.改变方向：将嵌合抗原受体T细胞疗法扩展至高危浆细胞异常增殖性疾病
Front Immunol. 2025 Apr 8;16:1558275. doi: 10.3389/fimmu.2025.1558275. eCollection 2025.
2
Piecing together the intricate puzzle of organ recovery in AL amyloidosis.拼凑AL淀粉样变性中器官恢复的复杂谜题。
Br J Haematol. 2024 Dec;205(6):2119-2121. doi: 10.1111/bjh.19810. Epub 2024 Oct 3.
3
Amyloidoses in Onco-Nephrology Practice: A Multidisciplinary Case-Based Conference Report.肿瘤肾脏病学实践中的淀粉样变性：一份基于多学科病例的会议报告。
Can J Kidney Health Dis. 2023 Apr 18;10:20543581231165711. doi: 10.1177/20543581231165711. eCollection 2023.
4
Diagnosis and Treatment of AL Amyloidosis.诊断与治疗 AL 型淀粉样变。
Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18.
5
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.轻链稳定：一种改善轻链型淀粉样变性的治疗方法。
Hemato. 2021 Dec;2(4):645-659. doi: 10.3390/hemato2040042. Epub 2021 Oct 5.
6
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).达雷妥尤单抗治疗轻链型淀粉样变性：托斯卡纳地区骨髓瘤网络（RTM）的真实病例经验
J Pers Med. 2022 Mar 17;12(3):484. doi: 10.3390/jpm12030484.
7
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients.在系统性 AL 淀粉样变性患者的真实队列中，尿 ACR 与 24 小时尿蛋白之间的相关性。
Blood Cancer J. 2020 Dec 11;10(12):124. doi: 10.1038/s41408-020-00391-2.
8
The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.淀粉样变论坛：推进 AL 淀粉样变药物研发的公私合作伙伴关系。
Orphanet J Rare Dis. 2020 Sep 29;15(1):268. doi: 10.1186/s13023-020-01525-2.
9
Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.系统性 AL 淀粉样变性：诊断与管理的当前方法
Hemasphere. 2020 Aug 10;4(4):e454. doi: 10.1097/HS9.0000000000000454. eCollection 2020 Aug.
10
Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.淀粉样轻链（AL）淀粉样变性患者抗体可变基因库破坏的多样模式。
PLoS One. 2020 Jul 7;15(7):e0235713. doi: 10.1371/journal.pone.0235713. eCollection 2020.
本文引用的文献
1
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.AL 淀粉样变性中器官反应的深度与改善的生存相关：器官反应标准的分级。
Leukemia. 2018 Oct;32(10):2240-2249. doi: 10.1038/s41375-018-0060-x. Epub 2018 Feb 20.
2
The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response.骨髓检查在轻链淀粉样变性患者达到完全缓解中的重要性。
Leukemia. 2018 May;32(5):1243-1246. doi: 10.1038/s41375-018-0022-3. Epub 2018 Jan 30.
3
Opening a can of worms in AL progression.在急性淋巴细胞白血病进展过程中引发一系列棘手问题。
Blood. 2018 Feb 1;131(5):475-476. doi: 10.1182/blood-2017-11-815423.
4
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.生长分化因子 15 是轻链淀粉样变性患者生存和肾脏结局的新型生物标志物。
Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.
5
AL amyloidosis: from molecular mechanisms to targeted therapies.AL 型淀粉样变性：从分子机制到靶向治疗。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):1-12. doi: 10.1182/asheducation-2017.1.1.
6
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.二线治疗在既往对非移植治疗敏感的 AL 淀粉样变性中的表现和结果。
Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.
7
Attitudes about when and how to treat patients with AL amyloidosis: an international survey.何时以及如何治疗 AL 淀粉样变性患者的态度：一项国际调查。
Amyloid. 2017 Dec;24(4):213-216. doi: 10.1080/13506129.2017.1370421. Epub 2017 Aug 31.
8
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.AL 淀粉样变性患者自体干细胞移植后二线治疗时机的划定。
Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14.
9
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.大剂量美法仑和干细胞移植后AL淀粉样变性的血液学复发
Blood. 2017 Sep 14;130(11):1383-1386. doi: 10.1182/blood-2017-06-788729. Epub 2017 Jul 11.
10
Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.利用纳米抗体富集结合 MALDI-TOF 质谱技术对 M 蛋白进行全面评估。
Clin Chem. 2016 Oct;62(10):1334-44. doi: 10.1373/clinchem.2015.253740. Epub 2016 Aug 18.
Zotero 插件